BPC-157
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It is one of the most extensively studied research peptides in the gut-repair and musculoskeletal-healing literature.
Part of KYIN Peptides' standard catalogue — see the product page for pricing.
What Is BPC-157?
BPC-157 traces back to 1975, when Predrag Sikiric — then a medical student at the University of Zagreb, Croatia — hypothesized that the stomach must produce a protective compound of its own to explain its remarkable ability to resist self-digestion and injury. Over the following years his research group investigated human gastric juice for exactly this kind of cytoprotective activity, and identified a protective protein they named “Body Protection Compound” (BPC). From that protein, the team isolated a much smaller, 15-amino-acid fragment that appeared responsible for much of BPC's biological activity — a synthetic pentadecapeptide, since this exact sequence has never been found circulating freely on its own in the body. The group published its landmark paper in 1991 and formally characterized the compound in 1993. See its full discovery history.
Research Focus
BPC-157 has since become one of the most extensively referenced compounds in gastrointestinal- and musculoskeletal-repair research literature. Because the original research question concerned the stomach's own self-protective mechanisms, gut-repair models remain a core focus, but the compound's research footprint has grown well beyond that starting point. It sits in KYIN's Healing & Recovery category alongside TB-500, GHK-Cu, and KPV, and is combined with all three in our KLOW Blend. See our Healing & Recovery research overview, or how it compares to TB-500, KPV, and GHK-Cu.
- Gastrointestinal repair research
- Musculoskeletal and tendon healing studies
- Angiogenesis research
Clinical & Preclinical Trial Data
No completed human clinical trials exist. A registered Phase I trial (42 healthy volunteers) was cancelled in 2016 with no published results, and the only human data available is a small 2025 pilot study of intravenous BPC-157 in 2 healthy adults, reporting no adverse effects. The evidence base is overwhelmingly animal and in-vitro research from Sikiric's group at the University of Zagreb, covering tendon healing, gut repair, and angiogenesis models.
In July 2026, an FDA advisory committee recommended BPC-157 for the 503A compounding bulks list — a non-binding vote, not FDA drug approval. Read what it actually means →
Availability
BPC-157 is part of KYIN Peptides' standard catalogue — see the product page for pricing, or contact us to order.
BPC-157 questions
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice, discovered by Predrag Sikiric's research group at the University of Zagreb. It is one of the most extensively studied research peptides in gut-repair and musculoskeletal-healing literature.
Has BPC-157 been tested in human trials?
No completed human clinical trials exist. A registered Phase I trial (42 healthy volunteers) was cancelled in 2016 with no published results, and the only human data available is a small 2025 pilot study of intravenous BPC-157 in 2 healthy adults, reporting no adverse effects. The evidence base is overwhelmingly animal and in-vitro research from Sikiric's group.
Does KYIN Peptides sell BPC-157?
Yes — BPC-157 is part of our standard catalogue, both individually and in our KLOW Blend and TB-500 + BPC-157 Blend. See the product pages for pricing.
Interested in BPC-157?
See pricing and order on the product page, or browse our other healing & recovery peptides.